{"id":"firmonertinib-mesilate-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Decreased appetite"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Firmonertinib is designed to target EGFR mutations commonly found in non-small cell lung cancer, particularly those resistant to first and second-generation EGFR inhibitors due to the T790M gatekeeper mutation. By covalently binding to the ATP-binding pocket of mutant EGFR, it prevents downstream signaling through the MAPK and PI3K/AKT pathways, leading to cancer cell growth inhibition and apoptosis.","oneSentence":"Firmonertinib mesilate is a third-generation EGFR tyrosine kinase inhibitor that irreversibly binds to and inhibits mutant EGFR, including T790M resistance mutations.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:12:42.118Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer with EGFR mutations including T790M resistance mutations"}]},"trialDetails":[{"nctId":"NCT06956001","phase":"PHASE3","title":"Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation","status":"RECRUITING","sponsor":"Allist Pharmaceuticals, Inc.","startDate":"2024-11-19","conditions":"EGFR, NSCLC (Advanced Non-small Cell Lung Cancer)","enrollment":300},{"nctId":"NCT06970639","phase":"PHASE3","title":"A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases","status":"RECRUITING","sponsor":"Allist Pharmaceuticals, Inc.","startDate":"2024-09-26","conditions":"NSCLC Patients With Brain Metastasis","enrollment":380},{"nctId":"NCT07182708","phase":"PHASE2","title":"High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-10-01","conditions":"NSCLC (Non-small Cell Lung Cancer), EGFR Activating Mutation, Resectable Lung Non-Small Cell Carcinoma","enrollment":62}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Firmonertinib Mesilate Tablets","genericName":"Firmonertinib Mesilate Tablets","companyName":"Allist Pharmaceuticals, Inc.","companyId":"allist-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Firmonertinib mesilate is a third-generation EGFR tyrosine kinase inhibitor that irreversibly binds to and inhibits mutant EGFR, including T790M resistance mutations. Used for Non-small cell lung cancer with EGFR mutations including T790M resistance mutations.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}